News
SGEN
228.74
+0.30%
0.65
Weekly Report: what happened at SGEN last week (0226-0301)?
Weekly Report · 03/04 09:12
Weekly Report: what happened at SGEN last week (0219-0223)?
Weekly Report · 02/26 09:13
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
Benzinga · 02/22 17:21
Weekly Report: what happened at SGEN last week (0212-0216)?
Weekly Report · 02/19 09:14
Weekly Report: what happened at SGEN last week (0205-0209)?
Weekly Report · 02/12 09:13
Weekly Report: what happened at SGEN last week (0129-0202)?
Weekly Report · 02/05 09:14
Pfizer Q4 results on deck amid gloomy earnings outlook
Seeking Alpha · 01/29 17:15
Weekly Report: what happened at SGEN last week (0122-0126)?
Weekly Report · 01/29 09:13
Weekly Report: what happened at SGEN last week (0115-0119)?
Weekly Report · 01/22 09:13
Pfizer faces setback in Enhertu patent dispute with Daiichi
Seeking Alpha · 01/17 12:08
Weekly Report: what happened at SGEN last week (0108-0112)?
Weekly Report · 01/15 09:13
Johnson & Johnson to acquire ADC developer Ambrx Biopharma for $2B
Seeking Alpha · 01/08 12:52
Weekly Report: what happened at SGEN last week (0101-0105)?
Weekly Report · 01/08 09:13
J.P. Morgan event in spotlight as biotech M&A, obesity frenzy, AI pick up
Seeking Alpha · 01/07 17:00
Pfizer: Paying Too Much To Boost Revenues
Seeking Alpha · 01/06 10:10
Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play
Seeking Alpha · 01/02 16:12
How To Earn $500 A Month From Pfizer Stock
Benzinga · 01/02 12:59
Weekly Report: what happened at SGEN last week (1225-1229)?
Weekly Report · 01/01 09:12
Pfizer in 2024: What to expect?
Seeking Alpha · 12/29/2023 15:48
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
Benzinga · 12/29/2023 12:04
More
Webull provides a variety of real-time SGEN stock news. You can receive the latest news about Seagen Inc through multiple platforms. This information may help you make smarter investment decisions.
About SGEN
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. It is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.